Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded
Chetan Ahya: I'm Chetan Ahya, Chief Asia economist
"Triple-Hormone-Receptor Agonist Retatrutide for Obesity." NEJM 2023;389:514526 FDA Prescription Drug User Fee Act (PDUFA) Guidelines FDA Center for Drug Evaluation and Research (CDER): NDA review process ClinicalTrials.gov: TRIUMPH Phase 3 program trial registry Historical obesity drug approval precedents: Semaglutide, Tirzepatide, Liraglutide Frequently Asked Questions Based on the current timeline, retatrutide FDA approval is expected in late 2027 to Q1 2028
Munji, R
:max_bytes(150000):strip_icc()/GettyImages-2260914806-2616be1382184e17a167d542d97230d7.jpg)
Use our Peptide Reconstitution Calculator for precise dosing.
US$ 22.59
US$ 24.78
US$ 23.16
US$ 27.37
US$ 20.33
US$ 24.20
US$ 20.46
